TTOOT2 Biosystems, Inc.

Nasdaq t2biosystems.com


$ 3.19 $ 0.14 (4.59 %)    

Thursday, 09-May-2024 15:59:35 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 3.19
$ 3.26
$ 0.00 x 0
$ 3.24 x 100
$ 3.18 - $ 3.60
$ 2.60 - $ 70.00
642,729
na
16.25M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-06-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-22-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-18-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-14-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-19-2018 12-31-2017 10-K
27 11-03-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-Q
29 05-08-2017 03-31-2017 10-Q
30 03-15-2017 12-31-2016 10-K
31 11-08-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 03-09-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-06-2015 03-31-2015 10-Q
38 03-04-2015 12-31-2014 10-K
39 11-05-2014 09-30-2014 10-Q
40 09-19-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 t2-biosystems-reiterates-guidance
T2 Biosystems Reiterates Guidance
05/06/2024 20:49:18

Reiterated 2024 Financial OutlookThe Company continues to expect full year 2024 total sepsis product revenue of $10.0 million t...

 t2-biosystems-q1-2024-gaap-eps-266-misses-227-estimate-sales-2061m-beat-2000m-estimate

T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(2.66) per share which missed the analyst consensus estimate of $(2.2...

 canaccord-genuity-maintains-hold-on-t2-biosystems-lowers-price-target-to-3

Canaccord Genuity analyst Kyle Mikson maintains T2 Biosystems (NASDAQ:TTOO) with a Hold and lowers the price target from $12...

 t2-biosystems-receives-notice-of-allowance-for-us-patent-titled-methods-and-systems-for-amplification-in-complex-samples-including-diagnostic-and-therapeutics-methods-for-pathogens-in-whole-blood

https://t.co/156OpGGCCy https://t.co/SCcZwLnY0d

 why-riot-platforms-shares-are-trading-higher-here-are-20-stocks-moving-premarket

Shares of Riot Platforms, Inc. (NASDAQ:RIOT) rose sharply in today's pre-market trading amid a rise in Bitcoin. Bitcoin ...

 t2-biosystems-announces-new-publication-highlighting-the-clinical-benefits-and-performance-of-the-t2resistance-panel

T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and anti...

 t2-biosystems-receives-extension-to-comply-with-nasdaq-listing-requirement

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION